Korean Circ J.  2018 Sep;48(9):854-856. 10.4070/kcj.2018.0156.

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension

• Jung HO

• KMID: 2418811
• DOI: http://doi.org/10.4070/kcj.2018.0156

Abstract

No abstract available.

MeSH Terms

Hypertension*

Reference

1. Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62:D42–D50.

2. Chung WJ, Park YB, Jeon CH, et al. Baseline characteristics of the Korean Registry of Pulmonary Arterial Hypertension. J Korean Med Sci. 2015; 30:1429–1438.

3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351:1425–1436.

4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142:448–456.

5. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122:156–163.

6. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008; 327:736–745.

7. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs. 2010; 11:1066–1073.

8. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013; 369:809–818.

9. Kim KH, Kim HK, Kim YJ, Chan SY, Sohn DW. Hemodynamic and histopathologic benefits of early treatment with macitentan in a rat model of pulmonary arterial hypertension. Korean Circ J. 2018; 48:839–853.

10. Kim KC, Lee JC, Lee H, Cho MS, Choi SJ, Hong YM. Changes in caspase-3, B cell leukemia/lymphoma-2, interleukin-6, tumor necrosis factor-α and vascular endothelial growth factor gene expression after human umbilical cord blood derived mesenchymal stem cells transfusion in pulmonary hypertension rat models. Korean Circ J. 2016; 46:79–92.